Skip to main content
Figure 2 | Genetic Vaccines and Therapy

Figure 2

From: A trial of somatic gene targeting in vivo with an adenovirus vector

Figure 2

Construction of the recombinant adenovirus AdNY58. The bacteriophage lambda LIA7 was recovered from the MutaMouse by in vitro packaging. An SmaI-SacI fragment of LIA7 within its lacZ gene was inserted into pIK153. The Tyr105Stop mutation (Figure 3) was introduced into the resulting plasmid (pIK153LZS.6) using site-directed mutagenesis by PCR as follows. The PCR products generated with the primer pair LZT-U (5'-CGAAGAGGCCCGCAC-3') and LZT-MA (5'-TAATGGGCTAGGTTACGTTGGTGTAG-3'), and the primer pair LZT-MS (5'-TAACCTAGCCCATTACGGTCAATCC-3') and LZT-D (5'-GGCAACATGGAAATCGC-3') were mixed and used as templates for the second PCR with the primer pair LTZ-U and LZT-D. Replacement of an FspI-AatII fragment of pIK153LZS.6 by the FspI-AatII fragment of the resulting PCR product resulted in pIK153 T10.1. A BamHI-SmaI fragment covering the lacZ gene of LIA7 was inserted into the BamHI site of pIK153 (resulting in pNY19). pNY21 was made by replacing the smaller SmaI-SacI fragment of pNY19 with the homologous SmaI-SacI fragment of pIK153T10.1, which carries the mutant sequence. An XbaI-BglII fragment of pNY21 was used to replace the smaller XbaI-BamHI fragment of pHM5 (resulting in pNY58). pAdNY58 was made by replacement of the smaller I-CeuI-PI-SceI fragment of pAdHM4 with an I-CeuI-PI-SceI fragment of pNY58. The longer PacI fragment of pAdNY58 was transfected into 293 cells. The recombinant adenovirus AdNY58 was prepared and purified from the cell culture.

Back to article page